Background: It was unknown whether human ␤-arrestin 2 could be SUMOylated. Results: Human ␤-arrestin 2 is SUMOylated on Lys-295. SUMOylation attenuates ␤-arrestin 2 inhibition of IL-1R/TRAF6 signaling. Conclusion: SUMOylation attenuates human ␤-arrestin 2 inhibition of TRAF6 and IL-1R signaling. Significance: We show SUMOylation as a novel mechanism in regulation of ␤-arrestin 2-mediated IL-1R-TRAF6 signaling.
IL-1 signaling is a key player in the regulation of inflammatory processes. IL-1 stimulates IL-1R and downstream signaling molecules and subsequently activates the transcription factors NF-B and AP-1, which control the expression of key immunoregulatory genes (1) (2) (3) . TRAF6 is a critical mediator for the Toll-like/interleukin-1 receptor superfamily (4, 5) . As a RING domain containing E3 ubiquitin ligase, TRAF6 is recruited to the receptor complexes and forms oligomers upon signaling activation and then leads to Lys-63-linked polyubiquitination of itself and downstream signaling molecules (6 -8) . Lys-63 ubiquitin-conjugated TRAF6 recruits TAB2 and activates the TAB2-associated TAK1 kinase, which subsequently phosphorylates and activates IB kinases. IB kinase then phosphorylates IB␣, leading to degradation of IB␣ and, consequently activation of NF-B. In addition, TAK1 can also activate the JNK and p38 MAPK family members, then triggering AP-1 activation (8 -10) . Both of oligomerization and autoubiquitination are critical for TRAF6 activity toward downstream targets to mediate IL-1␤-or LPS-induced NF-B/AP-1 activation.
␤-Arrestin 2 (also known as arrestin 3), along with ␤-arrestin 1 (arrestin 2) and visual rod (arrestin 1) and cone (arrestin 4) arrestins, is part of a small family of cytosolic adaptor proteins functioning as crucial adaptors/mediators in the regulation of a variety of cell surface receptor desensitization, trafficking, and signaling activities (11) (12) (13) . ␤-Arrestins have been shown to be modified by phosphorylation, ubiquitination, and nitrosylation (14 -16) . These modifications have linked ␤-arrestins to G protein-coupled receptor (GPCR) 3 internalization, trafficking and signal transduction (13) . Additionally, ␤-arrestin 2 directly interacts with TRAF6 after TLR/IL-1R activation, leading to prevention of autoubiquitination of TRAF6 and activation of NF-B and AP-1 (17) .
Recently, bovine ␤-arrestin 2 has been reported as a SUMOylated protein. The SUMOylation site Lys-400 locates within the C tail of bovine ␤-arrestin 2, which mediates GPCR endocytosis, and the SUMOylation of bovine ␤-arrestin 2 has been shown to promote ␤-arrestin 2-mediated ␤ 2 -adrenergic receptor internalization (18) . Here we also show human/murine ␤-arrestin 2 as a SUMOylated target. However, lysine 295, not lysine 400, has been identified as a major SUMO-conjugated site on human ␤-arrestin 2. We further found that SUMOylation decreases ␤-arrestin 2 inhibition of TRAF6 oligomerization and autoubiquitination and, consequently, promotes TRAF6-mediated NF-B/AP-1 activation. Our study reveals SUMOylation as a novel mechanism in the regulation of ␤-arrestin 2-mediated IL-1R/TRAF6 signaling.
EXPERIMENTAL PROCEDURES
Plasmids and Antibodies-The plasmids ␤-arrestin 2-HA, FLAG-TRAF6, and His-ubiquitin were provided by Dr. Ping Wang (Institute of Biomedical and Science, East China Normal University, China). FLAG-SUMO1, FLAG-SENP1, HA-SUMO1, RGS-SENP1, and RGS-SENP1-mu, a SENP1 catalytic mutant, have been described previously (19 -21) . ␤-Arrestin 2 point mutants (K295R and K400R) were generated using site-directed mutagenesis. SENP1-GFP, SENP1mu-GFP, and GFP-TRAF6 were generated using standard cloning procedures and PCR-based mutagenesis (Vazyme Biotech Co., Ltd). Antibodies against FLAG M2 and HA were from Sigma; GFP from Eptomics; RGS-his from Qiagen; and ␤-arrestin 2, IB␣, SUMO1, ERK, and p-ERK from CST.
Immunoprecipitation and Immunoblotting-Transfected cells were lysed in radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.1% SDS, 1% sodium deoxycholate, and a mixture of protease inhibitors) and cleared by centrifugation. Cleared cell lysates were incubated with 10 l of anti-FLAG M2-agarose affinity gel (Sigma) or 10 l of anti-HA-agarose affinity gel (Sigma) for 2 h. To perform an endogenous assay, MEF cells were lysed in ice-cold radioimmune precipitation assay buffer. Cleared cell lysates were incubated with anti-SUMO-1 antibody (1:200) and 15-20 l of protein A/G beads (Santa Cruz Biotechnology) for 4 h at 4°C. After extensive washing, beads were boiled at 100°C for 10 min. Proteins were resolved by SDS-PAGE and transferred onto PVDF membranes (Millipore), followed by immunoblotting using corresponding antibodies according to the instructions of the manufacturer. Immunoblots were analyzed using the LAS-4000 system (Fujifilm).
Ubiquitination Assay-HEK293T cells were transfected with His-ubiquitin and FLAG-TRAF6. The transfected cells were lysed by denatured buffer (6 M guanidine-HCl, 0.1 M Na 2 HPO 4 / NaH 2 PO 4 , and 10 mM imidazole), followed by Talon bead purification. The ubiquitination was detected by Western blot analysis.
Luciferase Assay-NF-B-or AP-1-dependent firefly luciferase plasmids were transiently transfected into HEK293T cells with Renilla luciferase plasmids and others. The cells were harvested 36 h after transfection, and luciferase assays were performed using the Dual-Luciferase reporter assay system (Promega). The relative luciferase activity was normalized on the basis of the Renilla luciferase activity. Data represent three independent experiments performed in duplicate.
Stable Cell Line-␤-Arrestin 2 WT or ␤-arrestin 2 K295R mutant (K295R) lentiviral plasmids were transfected into HEK293T cells with lentivirus packaging vectors by calcium phosphate-DNA coprecipitation method. Viral supernatants were collected 48 h after transfection. MCF-7 cells were infected by lentiviral supernatant in the presence of 10 g/ml Polybrene for 12 h. 48 -72 h later, the cells were sorted for stable cell lines by flow cytometry.
RNA Isolation and Real-time RT-PCR-Total RNA was isolated from cells by using Tripure isolation reagent (Roche). For mRNA analysis, an aliquot containing 2 g of total RNA was reverse-transcribed using the cDNA synthesis kit (Takara).
Real-time PCR was performed using SYBR Green PCR master mix (Applied Biosystems) and detected by the ABI Prism 7500 sequence detection system (Applied Biosystems). The primers for real-time RT-PCR were as follows: GAPDH, 5Ј-GAGCTG-AACGGGAAGCTCACTG-3Ј (sense) and 5Ј-TGGTGCTCA-GTGTAGCCCAGGA-3Ј (antisense); TNF␣, 5Ј-CCCTCTGG-CCCAGGCAGTCA-3Ј (sense) and 5Ј-ATGGGTGGAGGGG-CAGCCTT-3Ј (antisense).
ELISA Assay-After serum starvation for 12 h, MCF-7 cells were cultured for 24 h with recombinant human IL-1␤ (20 ng/ml) (Bioworld Technology). The concentration of TNF␣ in culture supernatants was determined with a human-specific ELISA kit (ExCell Bio), followed by analysis with a SYNERGY microplate reader (BioTek).
RESULTS

SUMO Conjugates
Human ␤-Arrestin 2 on Lys-295-Wyatt et al. (18) have reported previously that bovine ␤-arrestin 2 is conjugated by SUMO on residue Lys-400. However, when aligning the bovine, human, and murine ␤-arrestin 2 sequences, we noticed that the Lys-400 residue in human/murine ␤-arrestin 2 is not in a conserved SUMO consensus motif, ⌿KXE (Fig.  1A) , which raised the question of whether human/murine as well as bovine ␤-arrestin 2 could be SUMOylated. To test this, we performed an in vivo SUMOylation assay in HEK293T cells by cotransfecting human ␤-arrestin 2-HA and FLAG-SUMO1. As shown in Fig. 1 , B and C, the SUMOylated ␤-arrestin 2 band was readily detected in cells transfected with ␤-arrestin 2-HA and FLAG-SUMO1. We also observed that endogenous human/ mouse ␤-arrestin 2 was modified by endogenous SUMO1 in HEK293T cells and MEFs ( Fig. 1D and Fig. 3C ). These results showed that human/murine ␤-arrestin 2 could be also conjugated by SUMO similarly as bovine ␤-arrestin 2.
We mutated Lys-400 on human ␤-arrestin 2 to test whether this residue was a SUMO conjugation site, as bovine ␤-arrestin 2. As shown in Fig. 1E , mutating the Lys-400 residue had no significant effect on human ␤-arrestin 2 SUMOylation. However, when mutating Lys-295, a lysine residue located in a conserved SUMO consensus motif, LKHE (⌿KXE), human ␤-arrestin 2 SUMOylation was significantly abolished, suggesting that Lys-295, but not Lys-400, on human ␤-arrestin 2 is the major residue to accept SUMO.
SUMOylation Attenuates Human ␤-Arrestin 2 Inhibition of TRAF6 Activation-Lys-400 resides within the C tail of bovine ␤-arrestin 2, which mediates GPCR endocytosis. SUMOylation on this site has been shown to promote ␤-arrestin 2-mediated ␤ 2 -adrenergic receptor internalization (18) . However, Lys-295 on human ␤-arrestin 2 locates in the TRAF6-binding domain. ␤-Arrestin 2 binding to TRAF6 has been shown to inhibit autoubiquitination of TRAF6 and activation of NF-B and AP-1 responding to TLR-IL-1R signaling (17) . We therefore proposed that SUMOylation on Lys-295 might regulate ␤-arrestin 2 interacting with TRAF6 and then modulate IL-1R/ TRAF6 signaling. We first tested whether ␤-arrestin 2 SUMOylation is related to IL-1␤ stimulation. We showed that IL-1␤ induced human ␤-arrestin 2 SUMOylation ( Fig. 2A) . We then determined whether SUMOylation of human ␤-arrestin 2 could affect TRAF6 ubiquitination. As shown in Fig. 2B , the expression of ␤-arrestin 2 markedly reduced TRAF6 ubiquitination (lane 3 versus lane 2). Interestingly, the expression of SUMO1/Ubc9 could almost restore TRAF6 ubiquitination (Fig.  2B , lane 4 versus lane 3) but had no effect on ␤-arrestin 2 K295R-mutant (Fig. 2B , lane 5 versus lane 4). Mutating Lys-400 on human ␤-arrestin 2 did not affect TRAF6 ubiquitination (Fig. 2B , lane 6 versus lanes 3 and 4), suggesting that SUMOylation on Lys-295 reduces ␤-arrestin 2 inhibition of TRAF6 ubiquitination. We further tested whether SUMOylation of ␤-arrestin 2 had a similar effect on TRAF6-mediated NF-B and AP-1 activation as on TRAF6 ubiquitination. HEK293T cells were transfected with an NF-B-or AP-1-dependent luciferase reporter plus TRAF6 and with or without SUMO1/Ubc9. A luciferase assay from these transfected cells showed that SUMOylation on Lys-295 also attenuates ␤-arrestin 2 inhibition of NF-B and AP-1 activation (Fig. 2C) .
We generated human ␤-arrestin 2 wild-type, K295R-mutant, or K400R-mutant stably transfected MCF-7, a relatively low endogenous ␤-arrestin 2 cell line (data not shown), to further determine the role of SUMOylation in ␤-arrestin 2-mediated IL-1R signaling. As shown in tin 2 (K400R)-MCF-7 cells (Fig. 2E) . These results suggest that SUMOylation on Lys-295 could attenuate ␤-arrestin 2 inhibition of TRAF6 activation and TRAF6-mediated IL-1R signaling. SENP1 De-SUMOylates ␤-Arrestin 2-We observed that SUMO-specific protease 1 (SENP1) could bind to ␤-arrestin 2 (Fig. 3A) . Therefore, we reasoned that SENP1 could be a deconjugation protease for SUMOylated ␤-arrestin 2. To test this possibility, we performed a de-SUMOylation assay in the transfected cells. As shown in Fig. 3B , the expression of SENP1 wild-type but not the SENP1 catalytic mutant made the SUMOylated ␤-arrestin 2 band disappear. We further confirmed SENP1 as a specific de-SUMOylation protease of ␤-arrestin 2 by observing the accumulation of the SUMOylated ␤-arrestin 2 in Senp1 Ϫ/Ϫ MEFs (Fig. 3C ). Because SUMOylation reduces ␤-arrestin 2 inhibition of TRAF6 autoubiquitination and TRAF6-mediated NF-B/AP-1 activation (Fig. 2) , we speculated that SENP1 could enhance human ␤-arrestin 2 inhibition of TRAF6 ubiquitination and activation through de-SUMOylation. To test this, we performed an ubiquitination assay in HEK293T cells that were cotransfected with FLAG-TRAF6 and His-Ubiquitin plus ␤-arrestin 2-HA in the presence of SENP1-GFP wild-type or the catalytic mutant SENP1mu-GFP. As shown in Fig. 3D , the coexpression of SENP1 wild-type, not the catalytic mutant, and ␤-arrestin 2 decreased TRAF6 ubiquitination more than expression of ␤-arrestin 2 alone. Interestingly, SENP1-reduced TRAF6 ubiquitination depended on ␤-arrestin 2 because SENP1 action on TRAF6 ubiquitination could not be detected without the coexpression of ␤-arrestin 2. We also assessed the effect of SENP1 on TRAF6-mediated NF-B and AP-1 activation by using an NF-B-or AP-1-dependent luciferase assay. Similarly, SENP1 wild-type, not the catalytic mutant, can enhance ␤-arrestin 2 inhibition of TRAF6-mediated NF-B or AP-1 activation (Fig. 3E) .
We further determined the role of SENP1 in IL-1R signaling by using Senp1 Ϫ/Ϫ MEFs. As shown in Fig. 3F , IL-1␤ induced more TRAF6 ubiquitination in Senp1 Ϫ/Ϫ MEFs than that in wild-type MEFs. We also observed that IL-1␤-induced more TRAF6 ubiquitination in SENP1 knockdown ␤-arrestin 2 stably transfected MCF-7 cells (Fig. 3G ). More interestingly, there was no effect on ␤-arrestin 2 (K295R)-MCF-7 cells (Fig. 3G, lane 2  versus lane 4) , indicating that SENP1 negative regulation of TRAF6 ubiquitination is dependent on de-SUMOylation of ␤-arrestin 2. Similarly, IL-1␤ induced more IB␣ phosphorylation and ERK phosphorylation in Senp1 Ϫ/Ϫ MEFs than that in wild-type MEFs (Fig. 3H) . These data suggest that SENP1 enhances ␤-arrestin 2 inhibition of TRAF6-mediated signaling through de-SUMOylation of ␤-arrestin 2.
SUMOylation Decreases ␤-Arrestin 2 Binding to TRAF6 -␤-Arrestin 2 has been reported to directly interact with TRAF6 after TLR-IL-1R activation, leading to prevention of TRAF6 oligomerization and autoubiquitination (17) . Because SUMOylation on Lys-295 attenuates ␤-arrestin 2 inhibition of TRAF6 autoubiquitination and activation (Fig. 2) , we reasoned that SUMOylation might disrupt ␤-arrestin 2-TRAF6 interaction, which reduces ␤-arrestin 2 inhibition of TRAF6. To test this, we showed that the coexpression of SUMO1/Ubc9, which promotes ␤-arrestin 2 SUMOylation, could decrease both ␤-arrestin 2 wild-type and ␤-arrestin 2 K400R-mutant binding to TRAF6 (Fig. 4A, lanes 3 and 5 versus lane 2) but has no effect on ␤-arrestin 2 K295R-mutant (Fig. 4A, lane 4 versus lane 2) . Furthermore, we assessed ␤-arrestin 2-TRAF6 interaction in wildtype and Senp1 Ϫ/Ϫ MEFs. As shown in Fig. 4B , TRAF6 was able to bind to ␤-arrestin 2 in Senp1 Ϫ/Ϫ MEFs much less than that in wild-type MEFs. These results suggest that SUMOylation on Lys-295 could attenuate ␤-arrestin 2 binding to TRAF6.
Because oligomerization is necessary for TRAF6 autoubiquitination (8), we reasoned that SUMOylation of ␤-arrestin 2 would enhance TRAF6 oligomerization by attenuating ␤-arrestin 2 interaction with TRAF6. To test this, we cotransfected differently tagged TRAF6 into HEK293T cells. The coexpression of ␤-arrestin 2 reduced the association of GFP-TRAF6 with FLAG-TRAF6 (Fig. 4C, lane 3 versus lane 2) . Interestingly, the ␤-arrestin 2 K295R-mutant blocked TRAF6 oligomerization more efficiently than ␤-arrestin 2 wild-type did (Fig. 4C , lane 4 versus lane 3) , suggesting that SUMOylation of ␤-arrestin 2 could enhance TRAF6 oligomerization through disrupting the interaction between ␤-arrestin 2 and TRAF6.
Deficiency in SUMOylation Enhances ␤-Arrestin 2 Inhibition of IL-1␤-induced TNF␣ Expression-To determine the significance of ␤-arrestin 2 SUMOylation in vivo, we compared TNF␣ expression in ␤-arrestin 2 (WT)-MCF7 and ␤-arrestin 2 (K295R)-MCF7 cells. As shown in Fig. 5A , the expression of ␤-arrestin 2 wild-type reduced IL-1␤-induced TNF␣ mRNA expression. However, the expression of ␤-arrestin 2 K295R-mutant showed more of a reduction of the TNF␣ mRNA level than ␤-arrestin 2 wild-type. Furthermore, the ELISA assay confirmed that IL-1␤-treated ␤-arrestin 2 (K295R)-MCF7 cells produced much less TNF␣ in culture medium than ␤-arrestin 2 (WT)-MCF7 cells (Fig. 5B) . Taken together, these results indicate that SUMOylation attenuates ␤-arrestin 2 inhibition of IL-1␤-induced TNF␣ expression.
DISCUSSION
In this study, we identify Lys-295 as a major SUMOylation site on human ␤-arrestin 2. Because this site locates in the TRAF6-binding domain, SUMOylation can attenuate ␤-arrestin 2 binding to TRAF6. Therefore, SUMOylation of ␤-arrestin 2 can enhance TRAF6 oligomerization and autoubiquitination and, consequently, activate TRAF6-mediated IL-1R signaling. We also found SENP1 as a specific de-SUMOylation protease of ␤-arrestin 2 in these processes to enhance ␤-arrestin 2 inhibition of TRAF6 activation. These data reveal SUMOylation as a novel mechanism to attenuate ␤-arrestin 2 inhibition of TRAF6 and IL-1R signaling.
As an important adaptor, ␤-arrestins are widely involved in receptors, especially GPCR family, desensitization, trafficking, signaling, and regulating a growing list of cellular processes such as chemotaxis, apoptosis, inflammatory processes, and metastasis (13, 22) . More recently, studies have shown that ␤-arrestins function as scaffold proteins for many signaling molecules in the cytoplasm and nucleus, thereby regulating gene expression and cellular responses (23) . Besides traditional GPCR signaling, ␤-arrestins participate in the regulation of other signaling pathways, including TLR/IL-1R signaling and Wnt/␤-catenin signaling (17, 24 -26) . In TLR/IL-1R signaling, ␤-arrestin 2 has been reported to directly bind to TRAF6 and then reduce TRAF6 autoubiquitination and activation, leading to a negative regulation of TLR/IL-1R signaling. Here we further find ␤-arrestin 2 SUMOylation, as a negative mechanism, to attenuate ␤-arrestin 2 inhibition of TRAF6 activation and then promote TRAF6 oligomerization and autoubiquitination. SUMOylation is an essential posttranslational modification with critical roles in regulating protein functions such as localization, activity, and protein-protein interaction (27) (28) (29) . Typ-FIGURE 3. SENP1 de-SUMOylates ␤-arrestin 2. A, SENP1 binds to ␤-arrestin 2. HEK293T cells were transfected with the indicated plasmids, and the transfected cell lysates were immunoprecipitated (IP) with anti-FLAG M2-agarose beads, followed by WB analysis with anti-⌯〈 or anti-FLAG antibodies. IB, immunoblot; WCL, whole-cell lysate. B, SENP1 deconjugates SUMOylated ␤-arrestin 2 in vivo. HEK293T cells were transfected with the indicated plasmids, and the transfected cell lysates were immunoprecipitated with anti-FLAG M2-agarose beads. The immunoprecipitates and the whole-cell lysates were analyzed by immunoblotting with anti-␤-arrestin 2, anti-FLAG, or anti-RGS-his antibodies. MU, mutant. C, SUMOylated ␤-arrestin 2 is accumulated in Senp1 Ϫ/Ϫ MEFs. MEF cell lysates were immunoprecipitated with anti-SUMO1 antibody or control IgG. The immunoprecipitates and cell lysates were analyzed by immunoblotting with anti-␤-arrestin 2 or anti-SUMO1 antibodies. D, SENP1 enhances ␤-arrestin 2 inhibition of TRAF6 autoubiquitination. The indicated plasmids were transfected into HEK293T cells. The cell lysates were purified by Talon beads. The precipitates and cell lysates were immunoblotted using anti-FLAG, anti-HA, or anti-GFP antibodies. E, SENP1 enhances ␤-arrestin 2 inhibition of TRAF6-mediated NF-B and AP-1 activation. The indicated plasmids were cotransfected into HEK293T cells with an NF-B-or AP-1-dependent firefly luciferase reporter and a Renilla luciferase reporter. The relative luciferase activity was measured 36 h after transfection and normalized on the basis of Renilla luciferase activity. *, p Ͻ 0.05; **, p Ͻ 0.01. F, FLAG-TRAF6-transfected wild-type and Senp1 Ϫ/Ϫ MEFs were treated with IL-1␤ or left untreated before harvest. The cell lysates were immunoprecipitated with anti-FLAG M2-agarose beads, followed by WB analysis with anti-ubiquitin or anti-TRAF6 antibodies. G, ␤-arrestin 2 WT-or ␤-arrestin 2 K295R-MCF-7 stable cells were transfected with HA-TRAF6 and si-SENP1 or si-NS oligonucleotides. The cells were treated with IL-1␤ before harvest, the cell lysates were immunoprecipitated with anti-HA-agarose beads, and the immunoprecipitates and the cell lysates were analyzed by immunoblotting with anti-ubiquitin, anti-HA, or anti-FLAG antibodies. H, wild-type and Senp1
Ϫ/Ϫ MEFs were treated with IL-1␤ for the indicated time before harvest, followed by WB analysis with the indicated antibodies. Precipitates and cell lysates were analyzed by WB with anti-␤-arrestin 2 or anti-TRAF6 antibodies. C, GFP-TRAF6 and FLAG-TRAF6 were cotransfected into HEK293T cells with ␤-arrestin 2-HA wild-type or K295R-mutant, and the transfected cells were harvested 24 h after transfection. The cell lysates were immunoprecipitated with anti-FLAG M2-agarose beads. The precipitates and cell lysates were analyzed by WB with anti-GFP, anti-FLAG, or anti-HA antibodies.
ically, SUMO-modified proteins contain a SUMO consensus motif defined as ⌿KXE, where ⌿ is a large hydrophobic residue and X represents any amino acid (30) . Bovine ␤-arrestin 2 has been shown to be SUMOylated. SUMOylation of bovine ␤-arrestin 2 does not influence the affinity of receptor interaction but is important for AP-2 interaction and AP-2-mediated receptor internalization (18) . However, the Lys-400 residue in the carboxyl-terminal region of human ␤-arrestin 2 is not a major SUMOylation site because mutation of this site did not significantly affect its SUMOylation status. We identified Lys-295 as a major SUMOylation site on human ␤-arrestin 2, although there might be other potential SUMOylation sites. This site locates in the TRAF6-binding domain of human ␤-arrestin 2. Therefore, we observed that SUMOylation of human ␤-arrestin 2 plays a role in the regulation of TRAF6 activation and TRAF6-mediated signaling. It would be interesting to study whether it is evolution-related that the different SUMOylation sites exist on bovine and human/murine ␤-arrestin 2. In summary, our study reveals that SUMOylation modulates human ␤-arrestin 2-mediated inhibition of TRAF6 and TRAF6-mediated IL-1R signaling (Fig. 6 ). 
